Immunome, Inc. (IMNM)

Immunome's stock has experienced significant volatility with a 268.30% increase between April 4, 2025, and April 2, 2026. CEO Clay Siegall purchased 25,450 shares in late March 2026, while CSO Jack Higgins and CFO Max Rosett sold 9,438 and 63,656 shares, respectively, in early April 2026. The company reported positive Phase III data for varegacestat and Phase 1 oncology data for IMNN-101, and IM-3050 received IND clearance in April 2025. Immunome reported its full-year 2025 financial results on March 3, 2026, with a Q4 EPS of ($0.75) missing the consensus of ($0.65), and completed a follow-on equity offering of $200 million. Analysts maintain a consensus "Moderate Buy" rating.

Information detailing demand seasonality for Immunome, Inc.'s products and services is limited, as the company is a clinical-stage biotechnology firm. Its value is heavily influenced by clinical trial milestones, regulatory approvals, funding, partnerships, and broader biotech sector trends. A seasonal chart analysis suggests a period of seasonal strength from June 20 to September 30, aligning with the broader Healthcare sector's seasonal strength.

Immunome, Inc. is a clinical-stage biotechnology company focused on discovering and developing targeted oncology therapies. The company operates in the Healthcare sector and Biotechnology industry, advancing a portfolio of therapeutics including small molecules, ADCs, and radiotherapy candidates. Its pipeline programs include Varegacestat, a late-clinical stage gamma secretase inhibitor for desmoid tumors in Phase 3 trial; IM-1021, a ROR1-targeted ADC in Phase 1 trial; and IM-3050, a FAP-targeted radioligand expected to initiate a Phase 1 clinical trial in the second half of 2025. The preclinical pipeline features ADCs like IM-1617, IM-1340, and IM-1335, targeting undisclosed targets in solid tumors.

Immunome, Inc. is headquartered in Bothell, Washington, United States. The company's operations, including the discovery, design, development, manufacturing, and commercialization of its therapeutic products, are primarily conducted in the United States.

Immunome's brand reputation is tied to its clinical progress and financial activities. Positive Phase III data for varegacestat and the CEO's share purchase have boosted its reputation, while insider selling and unprofitability pose potential negative influences. Mixed early clinical trials also raise concerns about the efficacy of some therapies.

Immunome, Inc. has a mixed ownership structure. Approximately 63.07% to 73.93% of the company's stock is owned by institutional investors, with major holders including Fmr Llc and T. Rowe Price Investment Management, Inc. Insiders own approximately 4.79% of the stock. Public companies and individual investors own approximately 10.86% to 21.28% of the stock.